FDA Approves Lirafugratinib for Specific Advanced Cholangiocarcinoma

The FDA has approved lirafugratinib (Lyrfigtu, Elevar) for adults with previously treated, advanced or metastatic cholangiocarcinoma that harbors an FGFR2 gene fusion or other rearrangement. This approval, based on results from the REFOCUS clinical trial, offers a new targeted treatment option for this aggressive form of cancer. The new therapy provides an additional avenue for patients battling this challenging disease.